GLP-1s, Obesity, and Menopause: Benefits and Risks

Using GLP-1s for Obesity During Menopause: Benefits and Risks

Using GLP-1s for Obesity During Menopause: Benefits and Risks
iStock

For women with obesity, GLP-1 medications like Ozempic and Wegovy may help address the metabolic challenges that often intensify during midlife. The hormonal shifts of perimenopause and menopause can increase the risks of chronic diseases like diabetes and heart disease that GLP-1 drugs can help prevent or treat.

“Menopause isn’t a disease; it’s just a normal stage of life,” says Judi Chervenak, MD, a reproductive endocrinologist at Montefiore Health System in New York City. “However, as a woman matures, body fat increases and lean muscle decreases.” This shift makes metabolic complications even more likely.

GLP-1 medications may help improve key cardiovascular risk factors, such as cholesterol levels and abdominal fat. However, they aren’t without risks, some of which may be particularly relevant for women experiencing menopause, including gastrointestinal side effects and bone and muscle loss. Research on the interplay between menopause and these weight loss drugs is ongoing, so working with your doctor is essential when deciding whether these medications are right for you.

Graphic titled What to Know About Using GLP-1s During Menopause. Benefits - GLP-1s trigger fat reduction, especially around the belly, blood pressure and cholesterol improvements protect the heart, blood sugar levels may drop, lowering diabetes risk.
Everyday Health; Adobe Stock.

Benefit: Weight Loss

Weight changes are a reality for many women as they move toward menopause. An estimated 60 to 70 percent of women experience weight gain in midlife, adding an average of about 1.5 pounds to their body weight each year between the ages of 50 and 60.

This pattern commonly starts in perimenopause, when estrogen levels drop and the body begins storing fat differently. “The body shifts from a pear shape to an apple shape, with more fat accumulating around the belly,” says Dr. Chervenak. This visceral fat settles around the organs and is associated with greater risks of inflammation, insulin resistance, and cardiovascular disease.

GLP-1 medications may be especially effective at targeting this type of fat.

And when combined with menopausal hormone therapy, the effects may even be greater. In a study, postmenopausal women taking the GIP/GLP-1 medication tirzepatide (Mounjaro, Zepbound) in combination with menopausal hormone therapy saw greater reductions in their total body fat than those taking just tirzepatide (17 percent reduction versus 14 percent).

Hormone therapy isn’t intended for weight loss, but scientists continue to study whether it may affect how these medications work during the menopausal transition.

Benefit: Cardiovascular Protection

Heart disease can affect people at any stage of midlife, but a woman’s risk increases significantly after menopause. This rise is partly due to natural aging, but the drop in estrogen also plays a key role, says Chervenak.

Estrogen normally helps keep blood vessels flexible, so when levels fall, vessels can become stiffer, making them more prone to damage. And in blood vessels that are already less flexible or have cholesterol plaques, reintroducing estrogen in the form of hormone replacement therapy can increase the force and speed of blood flow with each heartbeat, sometimes causing a plaque in a vessel to break off and raising the risk of serious problems like heart attack, stroke, or blood clots, says Chervenak.

Research from large clinical trials suggests that GLP-1 medications may help lower those risks. For example, in the SELECT trial, semaglutide (Ozempic) reduced the chance of major cardiovascular events, including heart attack and stroke, by 20 percent in adults with obesity, demonstrating its potential to support heart health.

Clinical trials exploring the potential cardioprotective benefits of these drugs on postmenopausal women with obesity specifically are underway.

Benefit: Better Blood Sugar and Cholesterol

As women navigate the menopausal transition, their ovaries produce less 17-beta-estradiol, the body’s primary form of estrogen, says Chervenak. “When estrogen levels drop, bad cholesterol (LDL and triglycerides) tends to rise, good cholesterol (HDL) can fall, and insulin resistance increases,” she says.

GLP-1 medications can help counter these changes. “They help you feel full, slow gastric emptying, and support weight loss, in turn improving blood sugar control, pancreatic efficiency, and insulin response,” says Chervenak.

The dual GIP/GLP-1 medication tirzepatide (Mounjaro, Zepbound) can help lower bad cholesterol, raise good cholesterol, support weight loss, and improve blood sugar control, in turn helping the body respond better to insulin.

These effects aren’t exclusive to women in perimenopause or menopause, but they can benefit them too, due to the potential impacts of hormonal changes on metabolic health.

Benefit: Lower Blood Pressure

Blood pressure often becomes harder to manage during menopause as well. Since estrogen helps keep blood vessels flexible, arteries can stiffen when levels drop, resulting in a rise in blood pressure that forces the heart to work harder.

GLP-1 medications may help ease this strain in ways that extend beyond weight loss. By activating GLP-1 receptors in the brain, blood vessels, and kidneys — key systems that help regulate blood pressure and are commonly affected during menopause — these drugs can support healthier blood pressure and lower one’s risk of major heart events.

Risk: Bone and Muscle Loss

Rapid weight loss with GLP‑1 medications affects more than just body fat; it also reduces fat-free mass, including muscle, bone, connective tissue, and fluids. Typically, about 75 percent of weight loss comes from fat, with roughly 25 percent coming from fat-free mass, says Sriram Machineni, MD, an endocrinology, diabetes, and metabolism expert at Montefiore Health System in New York City.

Menopause already increases a woman’s risk of muscle loss (sarcopenia) and bone thinning (osteoporosis), so women using GLP‑1 medications during this transition should be especially vigilant. “Weight plays a tremendous role in bone density,” says Chervenak. “Women who lose large amounts of weight are at an increased risk for bone loss.”

Muscle loss is also a concern, particularly when physical activity is low, as there’s less stimulus for muscles to grow, says Dr. Machineni.

To minimize the risks of bone and muscle loss, experts recommended focusing on both protein intake and strength training.

You should include protein at every meal and snack, aiming to consume 1 to 1.5 grams of protein per kilogram of body weight daily, says Sangeeta Kashyap, MD, assistant chief of clinical affairs at New York-Presbyterian/Weill Cornell Medical Center. For example, a person weighing 150 pounds (68 kilograms) should try to eat roughly 70 to 100 grams of protein per day. Good sources of protein include eggs, Greek yogurt, chicken, fish, beans, and protein shakes.

When you’re on a GLP-1 medication, it’s also especially important to strength train at least two to three times per week, targeting all major muscle groups by using your body weight, dumbbells, resistance bands, or machines.

Push-ups, rows, squats, hip bridges, deadlifts, and lunges can be particularly effective exercises for strengthening major muscle groups simultaneously.

Risk: Digestive Side Effects

During perimenopause, dropping estrogen levels can reduce gut motility, often leading to uncomfortable gastrointestinal symptoms like gas and bloating.

GLP-1 medications also slow stomach emptying to help you feel full longer.

This combination can make abdominal discomfort feel much more intense.
Nausea is a common side effect of GLP-1 medications as well, affecting as many as 50 percent of users. It’s especially common in the first four to five weeks, as the rate at which food moves through the stomach slows down. While these symptoms usually dissipate as the body adjusts, they can make it difficult to eat.

Not eating is particularly risky during midlife. Menopause brings an enhanced need for specific nutrients, like protein for muscle and calcium for bones, that must be prioritized even when your appetite is low, says Chervenak. Most people can manage or even avoid these side effects with a few strategies, including staying hydrated and eating small, vitamin- and protein-rich meals throughout the day, even when the medication reduces your appetite.

Mixed: Mood and Mental Health

GLP-1 medications can affect mood differently for each person. Some report feeling more anxious or “emotionally flat,” but large studies don’t establish a clear increase in depression risk with these medications. In fact, research suggests that the use of these drugs is correlated with a lower likelihood of experiencing these mental health symptoms.

This connection may be particularly helpful for women navigating mood swings during menopause.

Because GLP-1 receptors influence mood and factors like blood sugar, appetite, and sleep, and because rapid body changes also play a role, experiences vary widely. That’s why doctors stress pairing these medications with balanced nutrition, healthy lifestyle habits, and regular check-ins regarding your mood.

“I’ve had many patients thank me, saying they feel like they’ve gotten their lives back,” says Chervenak. “They’re sleeping better because they’re happier, and they feel like themselves again.”

She reminds patients, though, that medication alone isn’t enough. “This medication isn’t going to be the cure for everyone,” she says. “Without changing diet and lifestyle, these drugs aren’t going to work.”

The Takeaway

  • GLP-1 medications like Wegovy and Zepbound can help women combat weight gain and body composition changes often triggered by the hormonal shifts of perimenopause and menopause.
  • These drugs may also improve heart health in perimenopausal and menopausal women by lowering blood pressure, reducing LDL cholesterol, and increasing insulin sensitivity, counteracting the increased risk of heart disease that occurs as estrogen levels decline.
  • A primary concern for menopausal GLP-1 users is the potential for accelerated bone thinning and muscle loss, which is why experts emphasize the necessity of a high protein intake and consistent strength training to mitigate these risks.
  • While GLP-1s can offer significant metabolic relief and even mood improvements in some users, doctors stress that they must be paired with healthy lifestyle habits and medical supervision to function optimally.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Kodoth V et al. Adverse Changes in Body Composition During the Menopausal Transition and Relation to Cardiovascular Risk: A Contemporary Review. Women’s Health Reports. June 13, 2022.
  2. Vergès B et al. Do Anti-Obesity Medical Treatments Have a Direct Effect on Adipose Tissue? Annales d’Endocrinologie. 2024.
  3. Combination of Obesity Medication Tirzepatide and Menopause Hormone Therapy Fuels Weight Loss. Endocrine Society. July 12, 2025.
  4. Lincolf A et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. November 2023.
  5. Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women. National Center for Biotechnology Information. July 9, 2025.
  6. Mahar MU et al. The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Obesity and Metabolic Syndrome. December 17, 2024.
  7. Ribeiro-Silva JC et al. The Blood Pressure–Lowering Effects of Glucagon-Like Peptide-1 Receptor Agonists: A Mini-Review of the Potential Mechanisms. Current Opinion in Pharmacology. April 2023.
  8. Protein. Harvard T.H. Chan School of Public Health.
  9. Tinsley GM et al. Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society. November 2024.
  10. Physical Activity Guidelines for Americans, 2nd Edition. U.S. Department of Health and Human Services.
  11. Functional Training: Compound Workouts for Fitness. National Academy of Sports Medicine.
  12. Digestive Health Issues More Common During Perimenopause and Menopause. The Menopause Society. October 10, 2025.
  13. Diabetes Drugs and Weight Loss. Mayo Clinic. November 14, 2024.
  14. Gorgojo-Martínez J et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated With GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine. December 24, 2022.
  15. Miller A et al. Most GLP-1 Medications Correlated With a Lower Likelihood of Anxiety and Depression Diagnoses. Epic Research. February 6, 2024.
  16. Turek J et al. Estrogen Fluctuations During the Menopausal Transition Are a Risk Factor for Depressive Disorders. Pharmacological Reports. January 14, 2023.
Allison Buttarazzi, MD

Allison Buttarazzi, MD

Medical Reviewer

Allison Buttarazzi, MD, is board-certified in internal medicine and lifestyle medicine, and is a certified health and well-being coach. In her primary care practice, Dr. Buttarazzi focuses on lifestyle medicine to help her patients improve their health and longevity, and her passion is helping patients prevent and reverse chronic diseases (like heart disease, high blood pressure, and diabetes) by improving their lifestyle habits.

She is a graduate of Tufts University School of Medicine and completed a residency at Maine Medical Center. Diagnosed with celiac disease during medical school, she realized the power of improving one's health through diet and lifestyle habits, which she later incorporated into her practice.

Susan Jara

Author

Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging content for diverse audiences of patients and caregivers. She specializes in patient education, health literacy, and SEO-driven content strategy, with expertise across chronic disease, mental health, addiction, arthritis, autoimmune conditions, and wellness.

Susan holds a bachelor’s degree in journalism and media studies from New York University’s Gallatin School of Individualized Study. Her career includes leadership roles at the Global Healthy Living Foundation and Health Monitor Network, where she developed multichannel health content across web, email, podcasts, video, social media, and print. Susan's work reaches millions of readers each year, and she collaborates with leading healthcare providers, researchers, advocacy groups, and industry partners to create resources that reach millions of readers each year.